HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. TARS | 0.00 |
HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:
TARS) with a Buy and maintains $88 price target.
